Drug intelligence / Profile preview

pertuzumab + taselisib + trastuzumab

Development stage: Unknown
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of two HER2-targeted monoclonal antibodies (pertuzumab and trastuzumab) plus a PI3K inhibitor (taselisib). This regimen is designed to provide dual HER2 blockade while simultaneously inhibiting the PI3K pathway, which is often activated in HER2-positive breast cancers and can contribute to resistance to HER2-targeted therapies. The combination therapy aims to overcome resistance mechanisms to HER2-targeted therapies, particularly those involving PI3K signaling.

Targets

HER2 ECD II (Human epidermal growth factor receptor 2 domain II)PIK3CA (Phosphoinositide 3-kinase alpha)

Beyond the preview

Go deeper on pertuzumab + taselisib + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pertuzumab + taselisib + trastuzumab.

Explore the full profile